Ginkgo Bioworks Holdings, Inc. (DNA) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2024. Ginkgo Bioworks operates as a horizontal platform for cell programming with two reportable segments: Cell Engineering (R&D services for customers across various industries) and Biosecurity (biomonitoring and bioinformatic support services). The company is currently executing a significant restructuring plan to reduce operational expenditures, including a workforce reduction of at least 35% and facility consolidation.
Key Financial Metrics
| Metric | Q2 2024 | Q2 2023 | YTD 2024 | YTD 2023 |
|---|---|---|---|---|
| Total Revenue | $56.2M | $80.6M | $94.2M | $161.3M |
| Net Loss | $(217.2M) | $(173.3M) | $(383.1M) | $(378.3M) |
| Loss Per Share (Diluted) | $(0.11) | $(0.09) | $(0.19) | $(0.20) |
| Operating Cash Flow | — | — | $(173.6M) | $(164.1M) |
| Cash & Equivalents | $730.4M | — | $730.4M | — |
| Goodwill Impairment | $47.9M | $0 | $47.9M | $0 |
| Restructuring Charges | $17.1M | $0 | $17.1M | $0 |
Note: YTD figures represent the six months ended June 30.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 30% year-over-year in Q2 2024. Cell Engineering revenue fell 20% ($36.2M vs $45.3M), while Biosecurity revenue dropped 44% ($20.0M vs $35.3M) due to the cessation of COVID-19 testing product revenue.
- Increased Losses: Net loss widened to $217.2M in Q2 2024 from $173.3M in Q2 2023. This was driven by a $47.9M goodwill impairment charge and $17.1M in restructuring charges, partially offset by lower operating expenses.
- Expense Reduction: Operating expenses decreased year-over-year due to the deconsolidation of Zymergen and reduced stock-based compensation. However, R&D and G&A expenses remain high relative to revenue.
- Investment Losses: The company recorded a $6.8M loss on investments in Q2 2024, including a $4.9M impairment on Genomatica preferred stock.
Guidance, Outlook, and Risks
- Restructuring Plan: Management announced a plan to reduce labor expenses by at least 35% and consolidate facilities. Estimated costs for the reduction in force range from $18.0M to $22.0M. Initial reductions began in June 2024, with completion expected in 2025.
- Commercial Strategy Shift: Starting in Q2 2024, the company changed commercial terms, removing downstream value share from certain program types and offering "lab-data-as-a-service" (LDaaS) to prioritize cash consideration over equity.
- NYSE Listing Risk: The company received notice from the NYSE that its Class A common stock price has fallen below $1.00 for 30 consecutive trading days. It has a six-month compliance period to regain a minimum closing price of $1.00 to avoid delisting.
- Internal Controls: A material weakness in internal control over financial reporting identified in 2023 remains present as of June 30, 2024. Remediation efforts are ongoing.
- Liquidity: With $730.4M in cash and cash equivalents, management believes it has sufficient liquidity to fund operations for at least the next 12 months.
Investor Verification Checklist
- Restructuring Execution: Verify the actual cost and timeline of the 35% workforce reduction and facility subleasing to ensure projected savings are realized.
- NYSE Compliance: Monitor the stock price trajectory to assess the risk of delisting within the six-month cure period.
- Revenue Mix: Track the shift from non-cash consideration (equity/SAFEs) to cash revenue in new Cell Engineering programs.
- Internal Controls: Review progress on remediation of the material weakness in financial reporting controls.
- Biosecurity Pivot: Assess the growth of new biomonitoring services to replace the lost COVID-19 testing revenue.